NEW YORK, Jan. 09, 2017 -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco, CA. The presentation is scheduled to take place on Thursday, January 12, 2017 at 10:30am PST. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
TGTX - G
CONTACT: Jenna Bosco Vice President- Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email: [email protected]


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Instagram Outage Disrupts Thousands of U.S. Users
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Washington Post Publisher Will Lewis Steps Down After Layoffs
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



